z-logo
open-access-imgOpen Access
Pharmacological and Immunohistochemical Characterization of a Mouse Model of Acute Herpetic Pain.
Author(s) -
Ichiro Takasaki,
Tsugunobu Andoh,
Makoto Nitta,
Hiroki Takahata,
Hideo Nemoto,
Kimíyasu Shiraki,
Hiroshi Nishimura,
Yasushi Kuraishi
Publication year - 2000
Publication title -
japanese journal of pharmacology/japanese journal of pharmacology
Language(s) - English
Resource type - Journals
eISSN - 1347-3506
pISSN - 0021-5198
DOI - 10.1254/jjp.83.319
Subject(s) - hyperalgesia , allodynia , nociception , medicine , morphine , analgesic , pharmacology , anesthesia , neuropathic pain , stimulation , subcutaneous injection , receptor
We have recently found that the infection with herpes simplex virus type-1 (HSV-1) of primary sensory neurons induces nociceptive hypersensitivity to noxious mechanical (hyperalgesia) and tactile stimulation (allodynia) in mice. In the present experiments, we determined the distribution of HSV-1 in the dorsal root ganglia and examined the effects of four analgesic agents on hyperalgesia and allodynia. HSV-1 was inoculated on the unilateral shin. HSV-antigen-positive cells were detected in the L4 and L5 dorsal root ganglia on days 5 and 7, but not day 3, post-inoculation. About 80% of the positive cells were small in size. Allodynia and hyperalgesia appeared on day 5 post-inoculation. Antinociceptive effects of analgesic agents were examined on day 6 post-inoculation. Morphine (1-5 mg/kg, subcutaneous) and gabapentin (10-100 mg/kg, peroral) dose-dependently inhibited both allodynia and hyperalgesia. Diclofenac (10-100 mg/kg, intraperitoneal) also produced antinociceptive effects, but there was a ceiling for the effect on hyperalgesia. Amitriptyline (3, 10 mg/kg, subcutaneous) did not affect allodynia and hyperalgesia. The results suggest that mechanical allodynia and hyperalgesia appeared when HSV-1 proliferated in the sensory neurons. This mouse model may be useful for studying the mechanisms of acute herpetic pain and anti-neuropathic pain agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here